



1-800-533-1710

<b>PATIENT NAME</b> TESTING, 83389		<b>PATIENT NUMBER</b> L3MRNW4075938		<b>AGE</b> 58	<b>SEX</b> F	<b>ACCESSION #</b> W4075938
<b>ORDERING PHYSICIAN</b>		<b>CLIENT ORDER #</b>			<b>ACCOUNT #</b> LIAISONS	
<b>COLLECTION</b> 04/22/11 11:59 A <b>DATE</b> <b>TIME</b>	<b>RECEIVED</b>  <b>DATE</b> <b>TIME</b>	<b>REPORT PRINTED</b> 04/25/11      10:06 A <b>DATE</b> <b>TIME</b>		<b>SPECIMEN INFORMATION</b> DATE OF BIRTH:		
Test Client Attn: Mayo Liaisons 200 First Street SW Rochester, MN 55905 507-284-8202						

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *
590G>A	G/A		MCR
759C>T	C/C		MCR
803A>G	A/G		MCR
845A>C	A/A		MCR
857G>A	G/G		MCR
859T>C/del	T/T		MCR
Reviewed By	John L. Black, M.D.		MCR

This test was developed and its performance characteristics determined by Laboratory Medicine and Pathology, Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

Bi-directional DNA sequencing is utilized to detect polymorphisms and other alterations in the NAT2 gene which is amplified by the polymerase chain reaction.

A number of drugs are acetylated by NAT2 including:

caffeine  
 caspofungin  
 dapsone  
 hydralazine  
 isoniazid  
 nitrazepam  
 procainamide  
 sulfonamides, including sulfadiazine, sulfamethazine, sulfapyridine, and sulfasalazine  
 zonisamide.

The NAT2 slow acetylator phenotype is associated with increased frequency of adverse drug reactions in some studies with several of these drugs (i.e. dapsone, isoniazid, sulfasalazine). Monitoring and some caution should be exercised when treating patients who are NAT2 slow acetylators. Drug concentrations should be verified in plasma or serum to be in the therapeutic ranges if dosing is

\* Perform Site Legend on last page of report

<b>PATIENT NAME</b> TESTING, 83389	<b>ORDER STATUS</b> Final	<b>COLLECTION DATE AND TIME</b> 04/22/11 11:59 A
---------------------------------------	------------------------------	---

1-800-533-1710

<b>PATIENT NAME</b> TESTING, 83389		<b>PATIENT NUMBER</b> L3MRNW4075938		<b>AGE</b> 58	<b>SEX</b> F	<b>ACCESSION #</b> W4075938
<b>ORDERING PHYSICIAN</b>		<b>CLIENT ORDER #</b>				<b>ACCOUNT #</b> LIAISONS
<b>COLLECTION</b> 04/22/11 11:59 A	<b>RECEIVED</b>	<b>REPORT PRINTED</b> 04/25/11 10:06 A		<b>SPECIMEN INFORMATION</b> DATE OF BIRTH:		
<b>DATE</b> <b>TIME</b>	<b>DATE</b> <b>TIME</b>	<b>DATE</b> <b>TIME</b>	<b>DATE</b> <b>TIME</b>			
Test Client Attn: Mayo Liaisons 200 First Street SW Rochester, MN 55905 507-284-8202						

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *
Sequencing	Performed		MCR

changed. Acetaminophen inhibits NAT2 enzymatic activity and should be used cautiously when treating slow acetylators who are receiving the drugs listed above.

## \* PERFORMING SITE

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First Street SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.
-----	---	--

<b>PATIENT NAME</b> TESTING, 83389	<b>ORDER STATUS</b> Final	<b>COLLECTION DATE AND TIME</b> 04/22/11 11:59 A
---------------------------------------	------------------------------	---